-
公开(公告)号:EP4419506A1
公开(公告)日:2024-08-28
申请号:EP22882888.5
申请日:2022-10-19
发明人: CHEN, Chiachun , DING, Xiao , LIU, Xiaosong , MENG, Qingyuan , REN, Feng , WANG, Hailong
IPC分类号: C07D239/80 , C07D403/02 , C07D403/14 , C07D487/04 , C07D519/00 , A61K31/519 , A61P35/00
CPC分类号: A61P35/00 , C07D487/04 , C07D401/04 , C07D403/04 , C07D471/04 , C07D413/14 , C07D239/95
-
公开(公告)号:EP3515896B1
公开(公告)日:2024-08-21
申请号:EP17850361.1
申请日:2017-06-23
IPC分类号: C07D257/02 , A61K31/395 , A61K49/22 , C07F5/00 , C07F9/6558 , C07D403/14 , C07D409/14 , C07D401/14 , C07D401/06
CPC分类号: A61K49/22 , C07D257/02 , C07D401/14 , C07F9/65583 , C07D401/06 , C07D403/14 , C07D409/14 , C07F5/003
-
公开(公告)号:EP4244217B1
公开(公告)日:2024-08-14
申请号:EP21807101.7
申请日:2021-11-10
IPC分类号: C07D401/14 , C07D403/14 , A01N43/56 , A01N43/60
CPC分类号: C07D401/14 , C07D403/14 , A01N43/56 , A01P13/02 , A01N43/54
-
公开(公告)号:EP4211116B1
公开(公告)日:2024-08-07
申请号:EP21773522.4
申请日:2021-09-06
IPC分类号: C07D231/14 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , A61K31/4166 , A61K31/4178 , A61P31/04
CPC分类号: C07D231/14 , C07D403/12 , C07D403/14 , C07D401/12 , C07D401/14 , A61P31/04
-
公开(公告)号:EP4406948A1
公开(公告)日:2024-07-31
申请号:EP22872006.6
申请日:2022-09-21
申请人: Sichuan Huiyu Pharmaceutical Co., Ltd. , Sichuan Huiyu Seacross Pharmaceutical Technology Co., Ltd.
发明人: CHEN, Shoujun , QIANG, Xiaoming , DING, Zhao , XIONG, Yong , WANG, Haibo , LIU, Ke , LIU, Mingdeng
IPC分类号: C07D401/14 , C07D239/72 , C07D471/04 , C07D403/14 , A61K31/517 , A61P35/00
CPC分类号: A61K31/517 , A61P35/00 , C07D239/72 , C07D401/14 , C07D403/14 , C07D471/04
摘要: A pyridine derivative and use thereof. The compound has an obvious inhibitory effect on the activity of KRAS and PI3K proteins, can be used as a KRAS and/or PI3K protein inhibitor, and can be used for preparing a drug for treatment of diseases such as KRAS or PI3K protein-mediated cancer. The compound has an extremely strong inhibitory effect on a KRAS G12C inhibitor (e.g. AMG-510) drug-resistant cancer cells , and has a wide application prospect thereof.
-
公开(公告)号:EP4402130A1
公开(公告)日:2024-07-24
申请号:EP22785862.8
申请日:2022-09-14
发明人: CHEN, Jinshan , CHOPRA, Rajiv , GU, Jiamin
IPC分类号: C07D237/14 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/14 , C07D417/14 , A61P35/00 , A61P31/12
CPC分类号: C07D237/14 , C07D403/12 , C07D403/04 , C07D403/14 , C07D405/14 , C07D401/14 , C07D417/14 , A61P35/00 , A61P31/12 , Y02A50/30
-
17.
公开(公告)号:EP4393917A1
公开(公告)日:2024-07-03
申请号:EP22869392.5
申请日:2022-09-16
发明人: WANG, Hongjun , FENG, Zewang , TIAN, Nana , ZHAO, Yanping , YANG, Jun , WEI, Lai , CAO, Xiangrong , CHEN, Jie
IPC分类号: C07D403/14 , A61K31/506 , A61P9/00 , A61P25/00 , A61P35/00 , A61P11/00
CPC分类号: A61K31/506 , A61P9/00 , A61P11/00 , A61P25/00 , A61P35/00 , C07D403/14
摘要: Provided are a solid form of a Rho-associated protein kinase inhibitor (6-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-1-methyl-1H-indol-2-yl)(3,3-difluoroazetidin-1-yl)methanone or a solvate thereof, a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and a use of the solid form as a Rho-associated protein kinase (ROCK) inhibitor, preferably a selective ROCK2 inhibitor.
-
公开(公告)号:EP4392423A1
公开(公告)日:2024-07-03
申请号:EP22861983.9
申请日:2022-08-23
发明人: YAN, Shunqi , YEH, Litain
IPC分类号: C07D451/14 , C07D475/12 , C07D491/048 , C07D498/14 , A61K31/517 , A61K31/519 , A61K31/5377 , A61P35/00 , C07D239/94 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/14 , C07D417/14
CPC分类号: A61P35/00 , C07D401/12 , C07D401/14 , C07D403/04 , C07D405/14 , C07D401/04 , C07D413/14 , C07D417/14 , C07D487/04 , C07D403/12 , C07D471/08 , C07D498/04
-
公开(公告)号:EP4389742A1
公开(公告)日:2024-06-26
申请号:EP22857877.9
申请日:2022-08-18
发明人: ZHANG, Chen , LIAO, Yuting , ZHU, Guozhi , TANG, Dachao , YU, Yan , TANG, Pingming , CHENG, Xinfan , LI, Yao , NI, Jia , YAN, Pangke
IPC分类号: C07D401/06 , C07D401/02 , C07D401/14 , C07D403/06 , C07D403/02 , C07D403/14 , A61K31/454 , A61P13/12
CPC分类号: A61K31/454 , A61P13/12 , C07D401/14 , C07D403/02 , C07D403/06 , C07D403/14 , C07D401/02 , C07D401/06
摘要: Provided are a compound as shown in general formula (I), or a stereoisomer, deuterate, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, a preparation method therefor, and the use thereof in the preparation of a drug for treating a disease associated with the activity or expression quantity of complement factor B.
-
公开(公告)号:EP4377310A1
公开(公告)日:2024-06-05
申请号:EP22757801.0
申请日:2022-07-28
IPC分类号: C07D403/12 , C07D403/14 , C07D495/04 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/30 , A61K31/497 , A61K31/506
CPC分类号: C07D495/04 , C07D403/12 , C07D403/14 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/30
-
-
-
-
-
-
-
-
-